Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Leukemia, Myeloid, Chronic-Phase 34Leukemia 30Leukemia, Myeloid, Acute 18Breast Neoplasms 18Recurrence 15Prostatic Neoplasms 14Leukemia, Lymphocytic, Chronic, B-Cell 13Neoplasm Metastasis 12Blast Crisis 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Pancreatic Neoplasms 10Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Lung Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Glioblastoma 7Melanoma 6Lymphoma 6Glioma 6Rectal Neoplasms 5Philadelphia Chromosome 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Indications Cancer × Dasatinib × Clear all
NCT02297139 2023-05-06

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Bristol-Myers Squibb

Phase 2 Completed
17 enrolled 12 charts

Multiple Indications Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡